Anorexia nervosa (AN) is a treatable brain-based disorder with long-term skeletal implications, adversely impacting bone health in a high percentage of sufferers. As AN frequently onsets in the adolescent years, and this period is also a time for acquisition of peak bone mass, intense exploration has surrounded pharmaceutical intervention in this age group to prevent adverse skeletal complications. Few randomized controlled trials (RCTs) have been conducted, and a recent systematic review found that transdermal estrogen administration resulted in significant areal bone mineral density (aBMD) increases in mature adolescents with AN [1], whereas administration of oral contraceptives has not significantly increased aBMD in RCTs [2]. Although bisphosphonates have some efficacy in adult women with AN, there have not been enough studies in adolescents to establish the safety or efficacy of this strategy in a younger age group ...
Language: en
", language="en", issn="1054-139X", doi="10.1016/j.jadohealth.2019.07.019", url="http://dx.doi.org/10.1016/j.jadohealth.2019.07.019" }